Breakthrough pneumococcal bacteraemia in patients treated with clarithromycin or oral β-lactams

被引:64
作者
Van Kerkhoven, D
Peetermans, WE
Verbist, L
Verhaegen, J
机构
[1] Univ Hosp Leuven, Dept Microbiol, B-3000 Louvain, Belgium
[2] Univ Hosp Leuven, Dept Internal Med, B-3000 Louvain, Belgium
关键词
S; pneumoniae; breakthrough bacteraemia; macrolides; beta-lactams;
D O I
10.1093/jac/dkg116
中图分类号
R51 [传染病];
学科分类号
100401 ;
摘要
The incidence of penicillin- and erythromycin-resistant strains of Streptococcus pneumoniae has increased considerably in Belgium. The medical charts of all patients with pneumococcal bacteraemia who were admitted to hospital over a period of 3 years (n = 136) were reviewed to identify treatment failure of outpatient antibiotic therapy. Twelve patients had received antibiotics for at least 48 h prior to admission. Four treatment failures received clarithromycin as pre-hospitalization therapy, and S. pneumoniae from all four patients were highly resistant to macrolides. Five patients failed on co-amoxiclav, whereas their S. pneumoniae were susceptible to penicillin and amoxicillin.This observation suggests that macrolide resistance is clinically relevant and leads to treatment failure, whereas suboptimal dosing may explain breakthrough pneumococcal bacteraemia in beta-lactam-treated patients.
引用
收藏
页码:691 / 696
页数:6
相关论文
共 23 条
[1]   Microbiological and pharmacodynamic considerations in the treatment of infection due to antimicrobial-resistant Streptococcus pneumoniae [J].
Appelbaum, PC .
CLINICAL INFECTIOUS DISEASES, 2000, 31 :S29-S34
[2]  
Bartlett John G., 2000, Clinical Infectious Diseases, V31, P347, DOI 10.1086/313954
[3]   Pharmacokinetic/pharmacodynamic parameters: Rationale for antibacterial dosing of mice and men [J].
Craig, WA .
CLINICAL INFECTIOUS DISEASES, 1998, 26 (01) :1-10
[4]  
DAGAN R, 1997, 37 INT C ANT AG CHEM
[5]   Mortality from invasive pneumococcal pneumonia in the era of antibiotic resistance, 1995-1997 [J].
Feikin, DR ;
Schuchat, A ;
Kolczak, M ;
Barrett, NL ;
Harrison, LH ;
Lefkowitz, L ;
McGreer, A ;
Farley, MM ;
Vugia, DJ ;
Lexau, C ;
Stefonek, KR ;
Patterson, JE ;
Jorgensen, JH .
AMERICAN JOURNAL OF PUBLIC HEALTH, 2000, 90 (02) :223-229
[6]  
FERRERO JL, 1990, DRUG METAB DISPOS, V18, P441
[7]   Appropriate use of antimicrobials for drug-resistant pneumonia:: Focus on the significance of β-lactam-resistant Streptococcus pneumoniae [J].
File, TM .
CLINICAL INFECTIOUS DISEASES, 2002, 34 :S17-S26
[8]   Bacteremic pneumonia due to multidrug-resistant pneumococci in 3 patients treated unsuccessfully with azithromycin and successfully with levofloxacin [J].
Fogarty, C ;
Goldschmidt, R ;
Bush, K .
CLINICAL INFECTIOUS DISEASES, 2000, 31 (02) :613-615
[9]   Importance of local variations in antibiotic consumption and geographical differences of erythromycin and penicillin resistance in Streptococcus pneumoniae [J].
García-Rey, C ;
Aguilar, L ;
Baquero, F ;
Casal, J ;
Dal-Ré, R .
JOURNAL OF CLINICAL MICROBIOLOGY, 2002, 40 (01) :159-164
[10]   Low dosage and long treatment duration of β-lactam -: Risk factors for carriage of penicillin-resistant Streptococcus pneumoniae [J].
Guillemot, D ;
Carbon, C ;
Balkau, B ;
Geslin, P ;
Lecoeur, H ;
Vauzelle-Kervroëdan, F ;
Bouvenot, G ;
Eschwége, E .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1998, 279 (05) :365-370